Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
about
Pharmacogenomics and personalized medicine: a review focused on their application in the Chinese populationVitamin E in human health and diseasePharmGKB summary: cyclosporine and tacrolimus pathwaysAssociation of MDR1 gene SNPs and haplotypes with the tacrolimus dose requirements in Han Chinese liver transplant recipients.Early non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients.Pyrosequencing to identify homogeneous phenomenon when using recipients/donors with different CYP3A5*3 genotypes in living donor liver transplantation.The correlation between post-operative fentanyl requirements and μ-opioid receptor gene A118G polymorphism in patients undergoing radical gastrectomy.Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update.Evaluation of CYP2C19, P2Y12, and ABCB1 polymorphisms and phenotypic response to clopidogrel in healthy Indian adultsCYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation.Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients.Association of CYP3A polymorphisms with the pharmacokinetics of cyclosporine A in early post-renal transplant recipients in China.Effect of CYP3A4∗1G and CYP3A5∗3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects.Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.Genes and beans: pharmacogenomics of renal transplant.The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis.Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature.Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients.Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.Effect of bifendate on the pharmacokinetics of talinolol in healthy subjects.Role of SLCO1B1, ABCB1, and CHRNA1 gene polymorphisms on the efficacy of rocuronium in Chinese patients.Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay.C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation.Effect of CYP3A4*1G on the fentanyl consumption for intravenous patient-controlled analgesia after total abdominal hysterectomy in Chinese Han population.CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine.Influence of the MDR1 haplotype and CYP3A5 genotypes on cyclosporine blood level in Chinese renal transplant recipients.CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.Effect of a new functionalCYP3A4polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients
P2860
Q28083875-A30F862F-6796-490D-B828-6D4AD3A0F0CEQ28291248-8FDF0ED4-2023-40E5-B9EB-6FE17F42B82BQ33989902-28E565F4-858F-4775-BD37-D81C89652437Q34081393-6CA77924-9802-41F9-B6DD-5A91CCBE1F88Q34511457-12B2BA18-04AB-47BB-A1FE-D81CB3F6461CQ34949176-D51AA1FD-C8AF-42DE-B01E-483AF47397A3Q36773493-A1740DF8-1F86-43BA-8405-7FD05CCEAE06Q37074093-2C63F101-ED57-482A-A2CD-923E34C109E6Q37167282-01EFD9D3-6FD3-4583-897F-8E880B4FD618Q37478703-C9170AC5-AD96-484F-811C-9A39B69E3A6FQ37634944-851CBF7A-EC20-4861-AD64-D9D577229EDBQ37646842-30B281CD-2C81-48A4-8464-9E2B0EFF4DD6Q37727173-62D26734-76E0-43E1-B8AE-A1992D0C3279Q37730915-AD9F3E08-7304-4182-A75C-B98E7100024BQ38063426-00FE74D2-5E8D-4A81-801A-ABE4CD462573Q38104742-924087D4-204A-4C70-8168-296F555D6CF6Q38299085-246DA4F2-AFB4-4C52-A3A9-69A0197A5F5AQ38414396-42AEE62C-2CC8-4C23-83C6-E8586671A35BQ38435024-C53B7722-60D2-465B-B00D-A0BB1AEEAD11Q38479485-7BFC7914-8182-4F98-A9B4-7A6AB5B84D1CQ43257603-6061D391-744B-4E62-91E1-8F1E1B130644Q46156964-1536D936-2AA8-44CE-A60B-8256DD2E4300Q46173047-8236C669-1E00-4FCD-949E-F5CCCBC191A1Q46709200-B8890E3C-39B8-4B27-8815-C8CE663CB519Q46959473-7C204634-773A-4BCA-9C77-92BFBBC9B27CQ48267196-A626E9A8-ED26-4684-A5D7-C84323F7BD49Q52921101-36AC65B2-23B9-4E8F-9524-F03638F5B6F7Q54453864-B727840D-B553-487F-BD31-39D558BA7156Q55280859-2A047392-6E64-4162-B601-A2DDE64479ECQ56834587-92312C12-EB9D-45D8-A0B9-6CF103FBF40E
P2860
Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Effects of genetic polymorphis ...... s after renal transplantation.
@en
Effects of genetic polymorphis ...... s after renal transplantation.
@nl
type
label
Effects of genetic polymorphis ...... s after renal transplantation.
@en
Effects of genetic polymorphis ...... s after renal transplantation.
@nl
prefLabel
Effects of genetic polymorphis ...... s after renal transplantation.
@en
Effects of genetic polymorphis ...... s after renal transplantation.
@nl
P2093
P2860
P1476
Effects of genetic polymorphis ...... s after renal transplantation.
@en
P2093
Gan-Ping Zhong
Hong-Hao Zhou
Jiang-Hua Tu
Li-Jun Zhu
Yong-Fang Hu
P2860
P304
P356
10.1111/J.1440-1681.2006.04492.X
P577
2006-11-01T00:00:00Z